Brazil Vaccine Market Growth Analysis Report - Market Size, Share, Forecast Trends and Outlook (2025-2034)
Market Report I 2025-06-20 I 250 Pages I EMR Inc.
The Brazil vaccine market was valued at USD 3.92 Billion in 2024 , driven by the surge in infectious disease cases and rising public-private partnerships in the region. The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034, with the values likely to reach USD 7.09 Billion by 2034 . The market is propelled by the growing public health infrastructure and high vaccination acceptance rates. Expanding adult vaccination programs and advancements in mRNA vaccine technologies are expected to fuel demand in the forecast period.
Brazil Vaccine Market Overview
A vaccine is a biological substance designed to stimulate the body's immune response against one or more specific diseases. It trains the immune system to recognize and combat pathogens, such as viruses or bacteria, by introducing harmless components or inactivated forms of the pathogen. This helps prevent future infections and supports public health through immunization. The market is expanding due to rising government immunization programs, increased awareness, and growing demand for COVID-19 and influenza vaccines, supported by both domestic production and international pharmaceutical collaborations.
Brazil Vaccine Market Growth Drivers
Surge in Dengue Cases to Drive Market Demand
The sharp rise in dengue fever cases is emerging as a significant growth driver for the market. According to data from the Brazilian Health Ministry, in February 2024, Brazil reported 262,247 dengue cases in the first four weeks, which is four times the number of cases recorded during the same period in 2023, creating an urgent demand for vaccination. This public health crisis, coupled with increasing vaccination demand, is set to substantially accelerate growth in the vaccine market in Brazil.
Brazil Vaccine Market Trends
Some of the notable trends in the market are the large-scale dengue vaccination initiative and robust collaboration between the federal government and the private sector:
Mass Dengue Vaccination Campaign to Boost the Market Growth
A notable trend in the market is the growing adoption of mass vaccination campaigns, driven by rising dengue cases. In January 2024, the city of Dourados launched the country's first large-scale dengue vaccination initiative, targeting 150,000 individuals aged 4 to 59. This strategic push is expected to enhance market growth, with increased demand for dengue vaccines in response to ongoing public health concerns.
Rising Partnerships to Enhance Brazil Vaccine Market Value
A growing trend in the market is the strong collaboration between the federal government and the private sector. This was highlighted by the launch of the Novo PAC program in August 2023, which earmarks investments in health infrastructure, including vaccine production and distribution. With BRL 31 billion allocated to health initiatives, this strategic partnership is expected to significantly boost the vaccine market, ensuring better access and distribution nationwide.
Brazil Vaccine Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- Multivalent Vaccines
- Monovalent Vaccines
Market Breakup by Type
- Subunit Vaccines
??- Recombinant vaccines
??- Conjugate Vaccines
??- Toxoid vaccines
- Inactivated
- Live Attenuated
- mRNA vaccines
- Viral vector vaccines
Market Breakup by Route of Administration
- Oral
- Parenteral
- Nasal
Market Breakup by Disease Indication
- Viral Diseases
??- Hepatitis
??- Influenza
??- HPV
??- MMR
??- Rotavirus
??- Herpes Zoster
??- Covid-19
??- Others
- Bacterial Vaccines
??- Meningococcal Diseases
??- Pneumococcal diseases
??- DPT
??- Others
- Cancer Vaccines
- Allergy Vaccines
Market Breakup by Age
- Pediatric
- Adult
Market Breakup by End User
- Hospital Pharmacies
- Retail Pharmacies
- Government Suppliers
- Others
Brazil Vaccine Market Share
The Viral Disease Segment Holds a Substantial Market Share
Based on the disease indication, the market is divided into viral diseases, bacterial vaccines, cancer vaccines, and allergy vaccines. Among these, viral diseases are expected to lead the vaccine market due to the ongoing global focus on infectious diseases such as influenza, COVID-19, and dengue. The growing demand for vaccines targeting these viruses, combined with advancements in vaccine technology, is anticipated to elevate the market value.
Brazil Vaccine Market Analysis by Region
The southeast region, including states like Sao Paulo and Minas Gerais, leads the Brazil vaccine market due to its high population density and advanced healthcare infrastructure. The south and central-west regions also show strong growth, driven by improved immunization programs and rising healthcare investments. These regions collectively account for the majority of vaccine demand and distribution.
Leading Players in the Brazil Vaccine Market
The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
GlaxoSmithKline plc
GSK plc, founded in 2000 and headquartered in Brentford, UK, is a global leader in healthcare and vaccines. The company plays a significant role in the Brazil vaccine market with its RSV vaccine, Arexvy, which is available in over 60 countries. At the International RSV Symposium in March 2024, GSK presented pivotal research on Arexvy, emphasizing its immunogenicity, safety, and efficacy, especially for older adults and immunocompromised individuals, addressing the growing demand for RSV vaccines in Brazil.
Merck & Co
Merck & Co., Inc., established in 1891, is a global leader in healthcare. The company, also known as MSD outside the United States and Canada, develops and manufactures vaccines for various diseases, including dengue, influenza, and COVID-19. Merck's global vaccination efforts, such as collaborations with Gavi, enhance vaccine access and confidence, supporting Brazil's vaccination initiatives in response to rising dengue cases.
Pfizer Inc
Pfizer is a key player in the market, producing a wide range of vaccines and medicines. It was established in 1849 and is headquartered in New York. In collaboration with Gavi, Pfizer has made significant contributions to vaccination efforts, including its pneumococcal conjugate vaccines. These vaccines, crucial for preventing pneumonia in children, support immunization initiatives, especially in vulnerable populations, and align with the country's broader health equity goals.
AstraZeneca plc
AstraZeneca plc, established in 1999, is headquartered in Cambridge, United Kingdom. In the Brazil vaccine market, AstraZeneca plays a crucial role with its COVID-19 vaccine, developed in partnership with the University of Oxford. Approved for emergency use in January 2021, the AstraZeneca vaccine has been integral to Brazil's national vaccination efforts during the pandemic.
Other key players in the market include Sanofi, Johnson & Johnson Services, Inc., and CSL Behring.
Key Questions Answered in the Brazil Vaccine Market Report
- What was the Brazil vaccine market value in 2024?
- What is the Brazil vaccine market forecast outlook for 2025-2034?
- What is the market segmentation based on product type?
- What is the market segmentation based on type?
- What is the market breakup based on the route of administration?
- How is the market segmented based on disease indication?
- How is the market divided based on age?
- How is the market divided based on the end user?
- What are the major factors aiding the Brazil vaccine market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major Brazil Vaccine market trends?
- Which product type is expected to dominate the market segment?
- Which type is projected to lead the market segment?
- Which route of administration is projected to lead the market segment?
- Which disease indication is projected to lead the market segment?
- Which age is anticipated to drive the market segment?
- Which end user is likely to dominate the market segment?
- Who are the key players involved in the Brazil vaccine market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
More Insights On
Vaccine Market
Saudi Arabia Vaccine Market
Japan Vaccine Market
Mexico Vaccine Market
Vietnam Vaccine Market
Latin America Vaccine Market
Asia Pacific Vaccine Market
United States Vaccine Market
India Vaccine Market
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Vaccine Market Overview
3.1 Latin America Vaccine Market Overview
3.1.1 Latin America Vaccine Market Historical Value (2018-2024)
3.1.2 Latin America Vaccine Market Forecast Value (2025-2034)
3.2 Brazil Vaccine Market Overview
3.2.1 Brazil Vaccine Market Historical Value (2018-2024)
3.2.2 Brazil Vaccine Market Forecast Value (2025-2034)
4 Brazil Vaccine Market Landscape*
4.1 Brazil Vaccine Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Brazil Vaccine Market: Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Type
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by Disease Indication
4.2.5 Analysis by Age
5 Brazil Vaccine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 PESTEL Analysis
5.3.1 Political
5.3.2 Economic
5.3.3 Social
5.3.4 Technological
5.3.5 Legal
5.3.6 Environment
5.4 Porter's Five Forces Model
5.4.1 Bargaining Power of Suppliers
5.4.2 Bargaining Power of Buyers
5.4.3 Threat of New Entrants
5.4.4 Threat of Substitutes
5.4.5 Degree of Rivalry
5.5 Key Demand Indicators
5.6 Key Price Indicators
5.7 Industry Events, Initiatives, and Trends
5.8 Value Chain Analysis
6 Brazil Vaccine Market Segmentation (218-2034)
6.1 Brazil Vaccine Market (2018-2034) by Product Type
6.1.1 Market Overview
6.1.2 Multivalent Vaccines
6.1.3 Monovalent Vaccines
6.2 Brazil Vaccine Market (2018-2034) by Type
6.2.1 Market Overview
6.2.2 Subunit Vaccines
6.2.2.1 Recombinant vaccines
6.2.2.2 Conjugate Vaccines
6.2.2.3 Toxoid vaccines
6.2.3 Inactivated
6.2.4 Live Attenuated
6.2.5 mRNA vaccines
6.2.6 Viral vector vaccines
6.3 Brazil Vaccine Market (2018-2034) by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Nasal
6.4 Brazil Vaccine Market (2018-2034) by Disease Indication
6.4.1 Market Overview
6.4.2 Viral Diseases
6.4.2.1 Hepatitis
6.4.2.2 Influenza
6.4.2.3 HPV
6.4.2.4 MMR
6.4.2.5 Rotavirus
6.4.2.6 Herpes Zoster
6.4.2.7 Covid-19
6.4.2.8 Others
6.4.3 Bacterial Vaccines
6.4.3.1 Meningococcal Diseases
6.4.3.2 Pneumococcal diseases
6.4.3.3 DPT
6.4.3.4 Others
6.4.4 Cancer Vaccines
6.4.5 Allergy Vaccines
6.5 Brazil Vaccine Market (2018-2034) by Age
6.5.1 Market Overview
6.5.2 Pediatric
6.5.3 Adult
6.6 Brazil Vaccine Market (2018-2034) by End User
6.6.1 Market Overview
6.6.2 Hospital Pharmacies
6.6.3 Retail Pharmacies
6.6.4 Government Suppliers
6.6.5 Others
7 Regulatory Framework
8 Patent Analysis
8.1 Analysis By Drug Type of Patent
8.2 Analysis by Publication Year
8.3 Analysis by Issuing Authority
8.4 Analysis by Patent Age
8.5 Analysis by CPC Analysis
8.6 Analysis by Patent Valuation
8.7 Analysis by Key Players
9 Clinical Trials Analysis
9.1 Analysis by Trial Registration Year
9.2 Analysis by Trial Status
9.3 Analysis by Trial Phase
9.4 Analysis by Therapeutic Area
9.5 Analysis by Geography
10 Funding and Investment Analysis
10.1 Analysis by Funding Instances
10.2 Analysis by Drug Class of Funding
10.3 Analysis by Funding Amount
10.4 Analysis by Leading Players
10.5 Analysis by Leading Investors
10.6 Analysis by Geography
11 Strategic Initiatives
11.1 Analysis by Partnership Instances
11.2 Analysis by Drug Class of Partnership
11.3 Analysis by Leading Players
11.4 Analysis by Geography
12 Supplier Landscape
12.1 GlaxoSmithKline plc
12.1.1 Financial Analysis
12.1.2 Product Portfolio
12.1.3 Demographic Reach and Achievements
12.1.4 Company News and Development
12.1.5 Certifications
12.2 Merck & Co.
12.2.1 Financial Analysis
12.2.2 Product Portfolio
12.2.3 Demographic Reach and Achievements
12.2.4 Company News and Development
12.2.5 Certifications
12.3 Sanofi
12.3.1 Financial Analysis
12.3.2 Product Portfolio
12.3.3 Demographic Reach and Achievements
12.3.4 Company News and Development
12.3.5 Certifications
12.4 Pfizer Inc.
12.4.1 Financial Analysis
12.4.2 Product Portfolio
12.4.3 Demographic Reach and Achievements
12.4.4 Company News and Development
12.4.5 Certifications
12.5 AstraZeneca plc
12.5.1 Financial Analysis
12.5.2 Product Portfolio
12.5.3 Demographic Reach and Achievements
12.5.4 Company News and Development
12.5.5 Certifications
12.6 Johnson & Johnson Services, Inc.
12.6.1 Financial Analysis
12.6.2 Product Portfolio
12.6.3 Demographic Reach and Achievements
12.6.4 Company News and Development
12.6.5 Certifications
12.7 CSL Behring
12.7.1 Financial Analysis
12.7.2 Product Portfolio
12.7.3 Demographic Reach and Achievements
12.7.4 Company News and Development
12.7.5 Certifications
13 Brazil Vaccine Market - Distribution Model (Additional Insight)
13.1 Overview
13.2 Potential Distributors
13.3 Key Parameters for Distribution Partner Assessment
14 Key Opinion Leaders (KOL) Insights (Additional Insight)
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.